Europe opens up big new market for Roche's RA therapy RoActemra

Roche ($RHHBY) just won access to a larger market for its RoActemra treatment for rheumatoid arthritis. The Swiss drugmaker got the nod from European regulators to sell the drug to treat patients in the first two years after diagnosis. Report (sub. req.)

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.